Bellerophon Therapeutics Inc

Bellerophon Therapeutics — Investor Presentation (January 2022)

25 slides from Bellerophon Therapeutics's investor presentation, Jan 5, 2022

  1. Slide 1: Company Presentation January 2022

    Slide 1: Company Presentation January 2022

    Company Presentation I January 2022Bellerophon Therapeutics

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Bellerophon Therapeutics Overview | January 20222 Forward Looking StatementsThispresentationcontainsforward-lookingstatementsthatinvolvesubstantialrisksanduncertainties.Allstatements,otherthanstatementsofhistoricalfacts,containedinthispresentation,includingstatementsregardingourstrategy,futureoperat

  3. Slide 3: Bellerophon Therapeutics (BLPH)

    Slide 3: Bellerophon Therapeutics (BLPH)

    Bellerophon Therapeutics Overview | January 20223 Bellerophon Therapeutics (BLPH)1. As of Sept 30, 2021; 2. Fully diluted Late-stage biotherapeutics company developing inhaled nitric oxide (iNO) therapies to address significant unmet need in serious cardiopulmonary disordersINOpulse inhaled nitric o

  4. Slide 4: Highly Experienced Leadership Team with Expertise in Respiratory & Rare Diseases

    Slide 4: Highly Experienced Leadership Team with Expertise in Respiratory & Rare Diseases

    Bellerophon Therapeutics Overview | January 20224 Highly Experienced Leadership Team with Expertise in Respiratory & Rare DiseasesMartin DekkerVP, Device Engineering & ManufacturingNaseem Amin, M.D.Chairman of the Board of DirectorsNicholas LacconaPrincipal Financial & Accounting Officer Peter Ferna

  5. Slide 5: INOpulse development pipeline

    Slide 5: INOpulse development pipeline

    Bellerophon Therapeutics Overview | January 20225 INOpulsedevelopment pipelineAddressing Unmet Needs in Multiple Cardiopulmonary Diseases IndicationPhase 1Phase 2Phase 3Current StatusfILDFibrotic InterstitialLung Disease at risk of Pulmonary HypertensionREBUILD trial recruitingUnderpinned by positiv

  6. Slide 6: Portable Delivery System Allows Chronic iNO Therapy

    Slide 6: Portable Delivery System Allows Chronic iNO Therapy

    Bellerophon Therapeutics Overview | January 20226 Portable Delivery System Allows Chronic iNO TherapyNitric Oxide is a well-established vasodilator being developed for ambulatory setting1. SoRelle, R.; Circulation, 1998, 2365-2366; 2. Furchgott, Ignarro, Murad 1998 Nobel Prize in Physiology or Medic

  7. Slide 7: Significant quality improvements achieved following introduction in 2016

    Slide 7: Significant quality improvements achieved following introduction in 2016

    Bellerophon Therapeutics Overview | January 20227 Significant quality improvements achieved following introduction in 2016INOpulse Delivery System performance in clinical trial setting95% improvement achieved in 2021 compared to 2016 across the INOpulse Device, Cannula and CartridgeActive continuous

  8. Slide 8: Preventing Ventilation/Perfusion Mismatch is Critical in PH

    Slide 8: Preventing Ventilation/Perfusion Mismatch is Critical in PH

    Bellerophon Therapeutics Overview | January 20228 Preventing Ventilation/Perfusion Mismatch is Critical in PH BaselineGeneralized vasodilation Reverses protective hypoxic vasoconstriction responseResults in ventilation / perfusion (V/Q) mismatch and worsened systemic oxygenationTargeted vasodilation

  9. Slide 9: A broad category of diffuse lung diseases with significant unmet need

    Slide 9: A broad category of diffuse lung diseases with significant unmet need

    Bellerophon Therapeutics Overview | January 20229 A broad category of diffuse lung diseases with significant unmet needFibrotic Interstitial Lung Disease (fILD) Normal IPFCharacterized by variable amounts of inflammation and fibrosis of lung air sacsIdiopathic Pulmonary Fibrosis (IPF) is the most co

  10. Slide 10: Pulmonary Hypertension associated with fILD Significantly Reduces Survival

    Slide 10: Pulmonary Hypertension associated with fILD Significantly Reduces Survival

    Bellerophon Therapeutics Overview | January 202210 Pulmonary Hypertension (PH) associated with fILDSignificantly Reduces SurvivalRivera-Lebron, Advances in Pulmonary Hypertension, 2013, 12:127-134; Tyvaso (inhaled Treprostinil) recently approved to improve 6MWD in PH-ILD Pulmonary Hypertension as Pr

  11. Slide 11: Acute Phase Data Showed Immediate Benefit of INOpulse on Vasodilation

    Slide 11: Acute Phase Data Showed Immediate Benefit of INOpulse on Vasodilation

    Bellerophon Therapeutics Overview | January 202211 Acute Phase 2 Data Showed Immediate Benefit of INOpulse on Vasodilation and Ventilation/Perfusion MatchingINOpulse Demonstrates Targeted Vasodilation in fILDSupporting the Mechanism of ActionHaijanet al., ATS 2017, Poster Presentation Targeted vasod

  12. Slide 12: Acute Hemodynamic Benefit in fILD

    Slide 12: Acute Hemodynamic Benefit in fILD

    Bellerophon Therapeutics Overview | January 202212 Clinically and statistically meaningful cardiopulmonary improvement on iNO30 with statistically significant benefit in PVR on dose escalation to iNO45Acute Hemodynamic Benefit in fILDSupports Continuing iNO45 in Phase 2b/3Bar graphs are median value

  13. Slide 13: Phase 2 Development in fILD used to Select Primary Endpoint

    Slide 13: Phase 2 Development in fILD used to Select Primary Endpoint

    Bellerophon Therapeutics Overview | January 202213 Exploratory trial designed to identify optimal endpoints and dose for Phase 3 trialPhase 2 Development in fILDused to Select Primary Endpoint PHASE 2Chronic studyCohort 1: n=41iNO30 vs placebo (1:1) 2-month blinded treatmentCohort 2:n=44iNO45 vs pla

  14. Slide 14: Phase 2 data supports use of MVPA as primary endpoint for Phase 3

    Slide 14: Phase 2 data supports use of MVPA as primary endpoint for Phase 3

    Bellerophon Therapeutics Overview | January 202214 Phase 2 data supports use of MVPA measurement as primary endpoint for Phase 3 trial14.6 min/day decline in MVPA on placebo; 2.3 min/day decline in MVPA on iNO45 at month 412.3 min/day (~21%) difference in time spent in MVPA as compared to placebo10-

  15. Slide 15: MVPA Results Mirrored Closely by Patient Reported Outcomes

    Slide 15: MVPA Results Mirrored Closely by Patient Reported Outcomes

    Bellerophon Therapeutics Overview | January 202215 Outcomes measured by UCSD Shortness Of Breath Questionnaire (SOBQ) and St. Georges Respiratory Questionnaire (SGRQ) remained stable on iNO45 vs. deterioration on placebo MVPA Results Mirrored Closely by Patient Reported Outcomes Change from baseline

  16. Slide 16: Phase 2 Safety Summary

    Slide 16: Phase 2 Safety Summary

    Bellerophon Therapeutics Overview | January 202216 INOpulse was well-tolerated in Cohort 1 and Cohort 2 Phase 2 Safety SummaryIncidence of SAEs was low in both active and placebo groupsand all reported as unrelated to study drugAEs were balanced and generally non-serious with no observable trends Co

  17. Slide 17: Data supported move to Phase 3 with MVPA as a primary endpoint

    Slide 17: Data supported move to Phase 3 with MVPA as a primary endpoint

    Bellerophon Therapeutics Overview | January 202217 Data supported move to Phase 3 with MVPA as a primary endpointPhase 2 fILDKey TakeawaysObserved meaningful effects on key activity levels and patient recorded outcomes (PRO)INOpulse(iNO30 and iNO45) group maintain activity levels while placebo group

  18. Slide 18: Pivotal Phase 3 Trial in fILD

    Slide 18: Pivotal Phase 3 Trial in fILD

    Bellerophon Therapeutics Overview | January 202218 FDA agreement on study design with MVPA as the primary endpointPivotal Phase 3 Trial in fILDOpen label extensionpatients continue oniNO45 or switch from placebo to iNO45 Primary EndpointChange in MVPA assessed by ActigraphySafetyAdditional Endpoints

  19. Slide 19: fILD Represents a Significant Market Opportunity in the US and Beyond

    Slide 19: fILD Represents a Significant Market Opportunity in the US and Beyond

    Bellerophon Therapeutics Overview | January 202219 fILDRepresents a Significant Market Opportunity in the USand BeyondSource: LEK INOpulse Market Research Report (2018); addressable population includes PH-ILD, with the majority on LTOT (long-termoxygen therapy); physician adoption rate based on prod

  20. Slide 20: INOpulse Could Address Multiple Large Market Opportunities

    Slide 20: INOpulse Could Address Multiple Large Market Opportunities

    Bellerophon Therapeutics Overview | January 202220 INOpulse Could Address Multiple Large Market Opportunities1. Huitema et al., NethHeart J, 2016, 24:390399; Nunes et al., Thorax, 2006, 61:6874; 2. Baughman et al., Annals ATS, 2016, 13:1244-1252; 3. Andersen KH et al. J Heart Lung Trans, 2012; 31:37

  21. Slide 21: Beyond fILD: Positive top-line Phase 2 data in PH-Sarcoidosis

    Slide 21: Beyond fILD: Positive top-line Phase 2 data in PH-Sarcoidosis

    Bellerophon Therapeutics Overview | January 202221 Dose-escalation study designed to verify acute hemodynamic effect of INOpulseBeyond fILD: Positive top-line Phase 2 data in PH-SarcoidosisAll 8 patients demonstrated decreases in mPAPand PVR across the doses of INOpulseutilized in the studyiNO45 dos

  22. Slide 22: INOpulse Demonstrates Acute Hemodynamic Improvement in PH-Sarc

    Slide 22: INOpulse Demonstrates Acute Hemodynamic Improvement in PH-Sarc

    Bellerophon Therapeutics Overview | January 202222 Pulmonary Vascular Resistance (PVR) mean Pulmonary Arterial Pressure (mPAP) INOpulse Demonstrates Acute Hemodynamic Improvement in PH-SarcBaseline mPAP: 37.2 mmHg Pulmonary hemodynamics measured via right heart catheterization at baseline and follow

  23. Slide 23: Beyond fILD: Targeted Delivery in PH-COPD Patients

    Slide 23: Beyond fILD: Targeted Delivery in PH-COPD Patients

    Bellerophon Therapeutics Overview | January 202223 Delivery to well ventilated pulmonary vessels and ventilation/vasodilation matchingBeyond fILD: INOpulseProvides Targeted Delivery and Improves Hemodynamics and Exercise Capacity in PH-COPD PatientsPatients completing 4 weeks of chronic treatment on

  24. Slide 24: Compelling Investment Opportunity in Late Stage Biotherapeutics Company

    Slide 24: Compelling Investment Opportunity in Late Stage Biotherapeutics Company

    Bellerophon Therapeutics Overview | January 202224 Compelling Investment Opportunity in Late Stage Biotherapeutics Company with Multiple High Value Indications1. As of Sept 30, 2021 Clinically validated approachNO is a proven, well-established vasodilator approved for acute use in persistent pulmona

  25. Slide 25: Investor Contacts

    Slide 25: Investor Contacts

    Investor Contacts Bellerophon Investor [email protected] Ritchie I LifeSci [email protected]

Source: SEC EDGAR · 8-K filed Jan 5, 2022

More decks from Bellerophon Therapeutics Inc